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Abstract
Background: Mammographic density (MD) is an established predictor of risk of a first breast cancer, but the
relationship of MD to contralateral breast cancer (CBC) risk is not clear, including the roles of age, mammogram
timing, and change with treatment. Multivariable prediction models for CBC risk are needed and MD could
contribute to these.
Methods: We conducted a case-control study of MD and CBC risk in phase II of the WECARE study where cases
had a CBC diagnosed ≥ 2 years after first diagnosis at age <55 years and controls had unilateral breast cancer (UBC)
with similar follow-up time. We retrieved film mammograms of the unaffected breast from two time points, prior
to/at the time of the first diagnosis (253 CBC cases, 269 UBC controls) and ≥ 6 months up to 48 months following
the first diagnosis (333 CBC cases, 377 UBC controls). Mammograms were digitized and percent MD (%MD) was
measured using the thresholding program Cumulus. Odds ratios (OR) and 95% confidence intervals (CI) for
association between %MD and CBC, adjusted for age, treatment, and other factors related to CBC, were
estimated using logistic regression. Linear regression was used to estimate the association between treatment
modality and change in %MD in 467 women with mammograms at both time points.
Results: For %MD assessed following diagnosis, there was a statistically significant trend of increasing CBC with
increasing %MD (p = 0.03). Lower density (<25%) was associated with reduced risk of CBC compared to 25 to < 50%
density (OR 0.69, 95% CI 0.49, 0.98). Similar, but weaker, associations were noted for %MD measurements prior to/at
diagnosis. The relationship appeared strongest in women aged < 45 years and non-existent in women aged 50 to 54
years. A decrease of ≥ 10% in %MD between first and second mammogram was associated marginally with reduced
risk of CBC (OR 0.63, 95% CI 0.40, 1.01) compared to change of <10%. Both tamoxifen and chemotherapy were
associated with statistically significant 3% decreases in %MD (p < 0.01).
Conclusions: Post-diagnosis measures of %MD may be useful to include in CBC risk prediction models with
consideration of age at diagnosis. Chemotherapy is associated with reductions in %MD, similar to tamoxifen.
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Background
Mammographic density (MD) has a well-established and
strong relationship with increased risk of first primary
breast cancer, with an odds ratio (OR) of 4.6 for high
versus low density categories in a large meta-analysis [1].
MD is defined as the area that appears white on a mam-
mogram in contrast to the dark non-dense or radiologic-
ally translucent area. Dense areas consist largely of
glandular and stromal tissue while non-dense areas are
largely adipose tissue. Percent MD (%MD) is the propor-
tion of the total breast area on the mammogram occu-
pied by dense tissue.
Breast cancer is the most common cancer in women
worldwide [2] and survival rates are high in developed
countries [3]. Thus, the population of breast cancer
survivors at risk of a second primary cancer is large and
increasing. In these women, the risk of developing
contralateral breast cancer (CBC) is higher than the risk
of developing a first breast cancer in the general popula-
tion [4]. Therefore, predicting and reducing CBC risk is
an important clinical consideration for breast cancer
survivors. In particular, effective means of CBC risk as-
sessment are needed for making decisions about prophy-
lactic contralateral mastectomy.
The recommended follow up for women who have
survived a first primary breast cancer includes annual
screening mammography of the contralateral breast [5],
making MD a feasible measure to contribute to the as-
sessment of CBC risk. There is some evidence showing
that higher MD at the time of a diagnosis of ductal car-
cinoma in situ (DCIS) is associated with increased CBC
risk [6–8]. Two large studies including women with both
DCIS and invasive cancer observed higher rates of any
second breast primary [9] or CBC [10] in women with
heterogeneously dense or extremely dense Breast Imaging
Reporting and Data System (BI-RADS) categories before
diagnosis compared to women with almost entirely fatty
breasts. Similar results were observed in women with in-
vasive breast cancer only [11]. However, another study of
women with invasive breast cancer did not identify associ-
ation between MD around the time of diagnosis and CBC
risk [12]. No previous study has specifically assessed MD
following treatment for a first primary breast cancer as a
risk factor for and potential predictor of CBC. One study
assessed changes in %MD between the baseline and
follow-up mammograms and found a statistically signifi-
cant reduction in CBC risk in women with a 10% or
greater decrease in %MD compared with women who had
a difference of < 10% [12]. MD generally decreases fol-
lowing tamoxifen use as reviewed elsewhere [13, 14]
and may also decrease with chemotherapy [12, 15].
Therefore, the effect of treatment should be considered
when assessing the role of MD in CBC risk. Furthermore,
it is not clear whether the timing of the mammogram with
respect to treatment influences the magnitude of any asso-
ciation with CBC risk.
We conducted a case-control study in patients with
CBC (cases) and controls with unilateral breast cancer
(UBC) to address the relationship between MD and
CBC risk and the associations between breast cancer
treatment modalities and changes in MD. We also
assessed the relationship between MD and CBC risk
specifically in younger women, which has not previously
been assessed. Mammograms prior to or at the time of
first diagnosis and mammograms obtained more than 6
months after that diagnosis were assessed for MD. The
study was conducted within phase II of the Women’s
Environmental Cancer and Radiation Epidemiology
(WECARE) study.
Methods
Study population
The WECARE Study is an international population-
based case-control study of women in which cases are
patients with asynchronous CBC and controls are pa-
tients with UBC. The study recruitment and data collec-
tion occurred in two phases, WECARE I (2001–2004)
and WECARE II (2009–2012), using similar study proce-
dures in all centers. As the WECARE MD study was
planned during WECARE II and only women recruited
during this phase were asked for consent to retrieve
their mammograms, only phase II is discussed further.
Each study center identified eligible women through one
or more population-based cancer registries. The three
US study centers recruited women from registries that
contribute to the NCI SEER Registry program: Seattle,
Washington; Iowa; and California. Additional recruit-
ment and data collection were conducted in Denmark
and in Ontario, Canada; however, Denmark did not par-
ticipate in the WECARE MD study.
WECARE study participants were diagnosed prior to
age 55 years, between 1990 and 2008, with a first pri-
mary local or regional-stage invasive breast cancer.
Cases were also diagnosed with a second primary inva-
sive CBC at least 2 years later with no intervening can-
cer diagnosis, other than a non-melanoma skin cancer
or cervical carcinoma in situ. UBC controls had no his-
tory of subsequent cancer diagnosis except for non-
melanoma skin cancer or cervical carcinoma in situ up
to their reference date, defined as follows. The reference
date for cases was the CBC diagnosis date, while for
controls it was defined by adding the interval between
the first breast cancer and the CBC for the matched case
to the date of breast cancer diagnosis for the control,
thus matching on follow-up time. Cases and controls
must also have been living in the same study reporting
area during the period from first breast cancer diagnosis
to the reference date. Additionally, controls must not
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have undergone prophylactic mastectomy of the contra-
lateral breast. All women had to be alive at the time of
contact for interview. When selected, each control was
individually matched to a case on year of birth (in 5-year
strata), year of diagnosis (in 4-year strata), cancer regis-
try region, race/ethnicity, and follow-up time as de-
scribed above. All study participants provided written
informed consent and the study was approved by the in-
stitutional ethics review boards at the University of Iowa
(IRB-01), Fred Hutchinson Cancer Research Center,
Cancer Prevention Institute of California, Mount Sinai
Hospital, and Memorial Sloan Kettering Cancer Center
and by the Committee for the Protection of Human
Subjects of the State of California.
Data and mammogram collection
WECARE study participants were interviewed by tele-
phone using a structured questionnaire that was de-
signed to obtain information about events occurring
before the diagnosis of the first primary breast cancer,
and events that occurred during the period between
diagnosis and reference date. The focus of the question-
naire was on currently known or suspected risk factors
for breast cancer, including personal demographics,
medical history, cancer family history, menstrual and re-
productive history, hormone use, body size, cigarette
smoking, and alcohol intake. Women were also asked if
and where mammograms were performed before and
after the first breast cancer diagnosis. Additionally,
medical records including pathology reports and hos-
pital charts were used to collect detailed treatment in-
formation (i.e., chemotherapy, hormonal therapy, and
radiation therapy) for the first primary breast cancer,
any recurrences experienced prior to the reference date
and characteristics of the first primary tumour (e.g., estro-
gen receptor (ER) status, histology).
Each participating study center attempted to obtain
two mammograms of the unaffected contralateral
breast in each woman, one as close as possible to the
period 12 months prior to diagnosis up to 1 month
post diagnosis (henceforth referred to as prior to/at
diagnosis) and one as close as possible to the period
of > 6 months up to 18 months post diagnosis
(henceforth referred to as post diagnosis). Only the
cranio-caudal view of the contralateral breast was used
in this study.
Mammogram digitization and MD measurement
The film mammograms were digitized at two locations,
Seattle (all US mammograms) and Toronto (Ontario
mammograms), both using a Kodak Lumisys Digital
Scanner. MD measurements were all done in Toronto
by one experienced reader (KB) using Cumulus [16], a
standard computer-assisted thresholding program used to
estimate the total area and dense area of the breast from
which %MD is calculated (dense area/total area × 100).
Mammograms were read in batches with both mammo-
grams from the same woman read in the same batch.
Mammogram order within each batch was randomized
prior to reading and the reader was blinded to case-
control status and time sequence of the mammogram.
Each batch included approximately the same number of
cases and controls. We randomly selected 10% of each
batch for repeat readings within and between batches. The
Pearson correlation was 0.94 for both intra- and inter-
batch repeats.
Statistical analysis
Although the original selection of cases and controls in
the WECARE study was individually matched, we were
not always able to obtain mammograms from both
members of a matched pair. Thus, to maximize statis-
tical power, we used unconditional logistic regression
to evaluate the relationship between %MD and CBC
risk, categorizing %MD as < 25%, 25 to < 50%, and ≥
50% in all mammograms available at each time point.
These categories are based on those used in a large
meta-analysis of %MD [1] with the modification of
combining the two lowest and two highest categories to
avoid sparse data at the extreme ends. The middle
group, with %MD of 25 to < 50%, is defined as the ref-
erence category. The odds ratio (OR) and 95% confi-
dence interval (CI) were estimated for each category. In
addition, a p value for trend was estimated using con-
tinuous data. The %MD prior to/at diagnosis was ana-
lyzed separately from %MD post diagnosis. Before
further analysis, we assessed the impact of various time
window definitions prior to/at diagnosis and post diag-
nosis, since the mammograms obtained were often
taken outside our ideal time frame. We did this by re-
running a basic model with %MD categories along with
three factors known to be strongly associated with
%MD - age, menopausal status, and estimated body
mass index (BMI) at the time of the mammogram -
using different time window definitions. Menopausal
status (premenopausal or postmenopausal) at the time
of the mammogram was derived from reported infor-
mation on menstrual status and time of last period re-
ported during the interview and BMI at the time of the
post-diagnostic mammogram was estimated from the
BMI reported at first breast cancer diagnosis and at
reference date, using linear interpolation. The reported
BMI at first diagnosis was used in models of %MD prior
to/at diagnosis. There was little variation in the OR esti-
mates across time-window definitions (Additional file 1:
Table S1). Therefore, we included any pre-diagnostic
mammogram up to 3 years prior to diagnosis and we
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selected 4 years after diagnosis as the upper limit for post-
diagnostic mammograms.
In subsequent models we also included the following
factors that have previously been associated with CBC
risk as well as matching factors used in the design of
phase II of the WECARE study: age at first diagnosis,
age at menarche, number of full-term pregnancies, first-
degree family history of breast cancer, study center, race
(non-Hispanic white versus other), characteristics of the
first tumour (histology, stage, and ER status), and use of
chemotherapy, radiation, and tamoxifen after first diag-
nosis. In addition to the primary analyses of %MD over-
all, we also considered %MD associations in subgroups
defined by age at first diagnosis, menopausal status at
the time of mammogram, breast cancer family history,
BMI, ER status, and treatment.
We assessed whether change in %MD (defined as the
difference between measurements of %MD between the
two time points) was associated with CBC in the subset
of women who had mammograms at both time points.
In this analysis we compared women with a decrease of
10% or more with women with a change of less than
10%. Few women had an increase in %MD of 10% or
more (6% of CBC cases and 7% of UBC controls) and
they were excluded. This model was adjusted for age at
first diagnosis, change in age, change in estimated BMI,
change in menopausal status, initial %MD, number of full-
term pregnancies, first-degree family history of breast can-
cer, study center, race (non-Hispanic white versus other),
characteristics of the first tumour (histology, stage, and ER
status), and use of chemotherapy, radiation, and tamoxifen
after first diagnosis.
To evaluate the association between different treat-
ment modalities and change in %MD, we used linear re-
gression with continuous change in %MD as the
dependent variable. The distribution of change in %MD
was approximately normal. These models were adjusted
for change in age and change in estimated BMI between
the two mammograms. We examined associations with
the treatment modalities (chemotherapy, radiation, and
tamoxifen) individually and also in the same model with
mutual adjustment. Note that other types of hormonal
therapies (e.g., aromatase inhibitors) were not common
in this population. We also examined common chemo-
therapy regimens and radiation categorized by dose
(none, <1Gy, ≥1Gy). We did not adjust for case-control
status as there was no association between change in
MD as a continuous variable and case-control status.
Results
We recruited 812 patients with CBC (cases) and 812
UBC controls in phase II of the WECARE study and we
were able to obtain at least one mammogram in 464 pa-
tients with CBC and 500 UBC controls. Women in
whom we could not obtain a mammogram in an appro-
priate time window (see below) were more likely to have
an earlier year of first breast cancer diagnosis (65% diag-
nosed in 1990–1996 versus 40% in 1990–1996) and to
be missing ER status (14% versus 6%), and were slightly
younger (mean age 45 years versus mean age 46 years).
Both groups had similar distributions of histologic type
(10% and 13% lobular), stage (68% and 66% local), and,
after excluding those with missing status, ER status (65%
and 68% positive). There were also no differences in
first-degree family history (27% and 28%). During the era
of the study nearly all mammograms were film rather
than digital. Given that MD assessment differs by mam-
mogram modality, we excluded the few mammograms
that were digital from the analysis (5 CBC cases and 6
UBC controls prior to/at first diagnosis, 39 CBC cases
and 41 UBC controls post diagnosis); we also excluded a
small number of films in which MD could not be read
because of poor image quality (4 CBC cases and 4 UBC
controls prior to/at first diagnosis, 11 CBC cases and 6
UBC controls post diagnosis). Based on sensitivity ana-
lyses comparing time windows as described in
“Methods”, we excluded mammograms taken more than
36 months prior to or 48 months following first diagno-
sis. Note that only one CBC case and one UBC control
mammogram occurred in the 1-month period following
diagnosis and likely prior to treatment initiation. The
final dataset includes mammograms from 362 CBC cases
(253 with mammograms prior to/at first diagnosis and
333 with mammograms post diagnosis) and 403 UBC
controls (269 with mammograms prior to/at first diag-
nosis and 377 post diagnosis). Among these, 467 women
(224 CBC cases and 243 UBC controls) had mammo-
grams at both time points. The median time between
mammograms was 1 year.
Relevant characteristics of the CBC cases and UBC
controls are shown in Table 1. Mean ages at first and
second mammogram were similar in the two groups as
were mean estimated BMI and distributions by center
and race. Of the women who had a mammogram avail-
able prior to/at diagnosis, 73% of women with CBC and
79% of UBC controls were premenopausal. The propor-
tion of women with CBC and UBC controls who were
premenopausal and had post-diagnostic mammograms
dropped to 39%.
Associations between %MD at two time points and
CBC risk
As shown in Table 2, lower %MD measured post diagno-
sis was associated with reduced risk of CBC. When com-
pared to women with density 25 to <50%, the OR for
women with < 25% density was 0.69 (95% CI 0.49, 0.98).
The trend for increasing risk of CBC with increasing
%MD was statistically significant (p = 0.03). Similar, but
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attenuated, associations were seen for %MD measured
prior to/at diagnosis. The association between %MD and
CBC was most apparent in women < 45 years old
(Table 3). Risk was statistically significantly lower in
young women with %MD <25% post diagnosis and
marginally significant prior to/at diagnosis. There was
no apparent trend in women aged 50–54 years at either
time point. The interaction between age and %MD was of
Table 1 Characteristics of women with contralateral breast
cancer (CBC) (cases) and unilateral breast cancer (UBC) controls
CBC (n = 362) UBC (n = 403)
Mean (SD) Mean (SD)
Age at mammogram before/at
1st diagnosis (years)
46 (6) 46 (6)
Age at mammogram after
1st diagnosis (years)
47 (6) 47 (6)
Follow-up timea (years) 7.9 (3.8) 8.0 (4.0)
BMI at 1st diagnosis (kg/m2) 25.2 (5.5) 25.2 (5.7)
BMIb at mammogram after
1st diagnosis (kg/m2)
25.2 (5.4) 25.8 (5.7)
Percent mammographic density
before/at 1st diagnosis
37.6 (18.1) 35.8 (18.3)
Percent mammographic density
after 1st diagnosis
31.4 (18.3) 28.0 (16.7)
N (%) N (%)
Study center
Northern California 179 (49) 213 (53)
Seattle 82 (23) 80 (20)
Ontario 52 (14) 64 (16)
Iowa 49 (14) 46 (11)
Race
Non-Hispanic white 295 (83) 334 (81)
Other 67 (17) 69 (19)
Histologic type at 1st diagnosis
Non-lobular 321 (89) 353 (88)
Lobular 41 (11) 50 (12)
Stage at 1st diagnosis
Local 251 (69) 254 (63)
Regional 106 (29) 143 (35)
Missing 5 (1) 6 (1)
Estrogen receptor at 1st diagnosis
Positive 213 (59) 273 (68)
Negative 129 (36) 105 (26)
Missing 20 (6) 25 (6)
Chemotherapy at 1st diagnosis
Yes 236 (65) 272 (67)
No 126 (35) 131 (33)
Radiation at 1st diagnosis
Yes 251 (69) 179 (69)
No 111 (31) 124 (31)
Tamoxifen at 1st diagnosis
Yes 158 (44) 221 (55)
No 204 (56) 182 (45)
Family historyc of breast cancer
Yes 123 (34) 89 (22)
No 234 (65) 306 (76)
Adopted/missing 5 (1) 8 (2)
Table 1 Characteristics of women with contralateral breast
cancer (CBC) (cases) and unilateral breast cancer (UBC) controls
(Continued)
CBC (n = 362) UBC (n = 403)
Mean (SD) Mean (SD)
Age at menarche (years)
<13 194 (54) 193 (48)
≥13 167 (46) 209 (52)
Missing 1 (< 1) 1 (< 1)
Full-term pregnancies
None 101 (28) 95 (24)
1–3 241 (67) 278 (69)
≥4 20 (6) 30 (7)
SD standard deviation, BMI body mass index
aTime interval between first diagnosis and reference date defined as
time of second diagnosis in CBC cases and time of second diagnosis
in matched case for UBC controls
bBMI estimated from reported BMI at first diagnosis and reported BMI
at reference date using interpolation
cFirst-degree family history
Table 2 Association between %MD and CBC risk categories
prior to/ata diagnosis and post diagnosisb
CBC
Number (%)
UBC
Number (%)
ORc (95% CI)
Percent mammographic density prior to/at diagnosis
<25% 67 (26) 81 (30) 0.77 (0.49, 1.21)
25 to <50% 125 (49) 130 (48) 1.00
≥50% 61 (24) 58 (22) 1.17 (0.73, 1.87)
p trend 0.12
Percent mammographic density post diagnosis
<25% 129 (39) 181 (48) 0.69 (0.49, 0.98)
25 to <50% 152 (46) 155 (41) 1.00
≥50% 52 (16) 41 (11) 1.21 (0.74, 1.99)
p trend 0.03
Abbreviations: %MD percent mammographic density, CBC contralateral breast
cancer, UBC unilateral breast cancer, OR odds ratio, CI confidence interval
aPior to/at diagnosis was 36 months prior up to 1 month post diagnosis
bPost diagnosis was > 6 months up to 48 months post diagnosis
cOR adjusted for study center, race (non-Hispanic white versus other), age at
mammogram, menopausal status at mammogram, estimated body mass index
at mammogram, age at first diagnosis, age at menarche, number of full-term
pregnancies, first-degree family history of breast cancer, histologic type, stage,
estrogen receptor status of first diagnosis, chemotherapy, radiation, and
tamoxifen use after first diagnosis
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marginal significance (p = 0.06) post diagnosis. When sub-
groups were defined by menopausal status at mammo-
gram, the associations were somewhat stronger in
premenopausal than in postmenopausal women, but the
interaction p values were larger compared to those for in-
teractions with age group (Additional file 1: Table S2).
There was no evidence for interaction between first-degree
family history of breast cancer and %MD (Table 4). None
of the p values for interaction of %MD with BMI, ER status,
or any treatment modality were statistically significant
(all p ≥ 0.30).
Association between change in %MD and CBC risk
Compared to women with a difference of < 10% in %MD
between the two mammograms, women who had a de-
crease of ≥ 10% had reduced risk of CBC that was of
borderline statistical significance (Table 5).
Change in %MD with treatment
Chemotherapy and tamoxifen were each associated with
a statistically significant reduction in %MD (Table 6). In
a mutually adjusted model, the estimated effect of each
of these treatment modalities was similar (a reduction in
Table 3 Association of %MD categories prior to/at first
diagnosisa and post diagnosisb with CBC risk by age
CBC
Number (%)
UBC
Number (%)
ORc (95% CI)
Percent mammographic
density prior to/at diagnosis
Age <45 years
<25% 18 (20) 30 (30) 0.46 (0.20, 1.05)
25 to <50% 46 (51) 49 (49) 1.00
≥50% 26 (29) 21 (21) 2.22 (0.94, 5.25)
Age 45 to <50 years
<25% 19 (23) 25 (27) 0.86 (0.36, 2.06)
25 to <50% 39 (48) 46 (49) 1.00
≥50% 24 (29) 22 (24) 1.22 (0.51, 2.89)
Age 50–54 years
<25% 30 (37) 26 ((34) 0.87 (0.37, 2.04
25 to <50% 40 (49) 35 (46) 1.00
≥50% 11 (14) 15 (20) 0.60 (0.21, 1.68)
p interaction 0.39
Post diagnosis
Age <45 years
<25% 42 (34) 71 (52) 0.51 (0.27, 0.96)
25 to <50% 55 (45) 51 (37) 1.00
≥50% 26 (21) 15 (11) 1.70 (0.71, 4.05)
Age 45 to <50 years
<25% 36 (33) 57 (45) 0.60 (0.31, 1.16)
25 to <50% 54 (49) 57 (45) 1.00
≥50% 20 (18) 13 (10) 1.70 (0.68, 4.22)
Age 50–54 years
<25% 51 (51) 53 (47) 0.98 (0.52, 1.87)
25 to <50% 43 (43) 47 (42) 1.00
≥50% 6 (6) 13 (12) 0.51 (0.16, 1.87)
p interaction 0.06
Abbreviations: %MD percent mammographic density, CBC contralateral breast
cancer, UBC unilateral breast cancer, OR odds ratio, CI confidence interval
aPrior to/at 1st diagnosis was 36 months prior up to 1 month
post diagnosis
bPost diagnosis was > 6 months up to 48 months post diagnosis
cOR adjusted for study center, race (non-Hispanic white versus other), age
at mammogram, menopausal status at mammogram, estimated body mass
index at mammogram, age at first diagnosis, age at menarche, number
of full-term pregnancies, first-degree family history of breast cancer,
histologic type, stage, and estrogen receptor status of first diagnosis,
chemotherapy, radiation, and tamoxifen use after first diagnosis
Table 4 Association of %MD categories prior to/at first
diagnosisa and post diagnosisb with CBC risk by family historyc
CBC
Number (%)
UBC
Number (%)
ORd (95% CI)
Percent mammographic
density prior to/at diagnosis
No family history
<25% 44 (27) 64 (31) 0.73 (0.42, 1.27)
25 to <50% 81 (49) 97 (46) 1.00
≥50% 40 (24) 48 (23) 0.96 (0.54, 1.70)
Family history
<25% 22 (26) 16 (29) 0.95 (0.32, 2.86)
25 to <50% 43 (51) 30 (55) 1.00
≥50% 20 (24) 9 (16) 2.19 (0.62, 7.73)
p interaction 0.50
Post diagnosis
No family history
<25% 86 (39) 132 (46) 0.76 (0.50, 1.15)
25 to <50% 102 (47) 124 (44) 1.00
≥50% 30 (14) 28 (10) 1.28 (0.69, 2.36)
Family history
<25% 41 (37) 46 (53) 0.53 (0.25, 1.14)
25 to <50% 47 (43) 28 (33) 1.00
≥50% 22 (20) 12 (14) 1.55 (0.57, 4.22)
p interaction 0.59
Abbreviations: %MD percent mammographic density, CBC contralateral breast
cancer, UBC unilateral breast cancer, OR odds ratio, CI confidence interval
aPrior to/at 1st diagnosis was 36 months prior up to 1 month post diagnosis
bPost diagnosis was > 6 months up to 48 months post diagnosis
cFamily history is defined as having a first-degree relative (mother, sister,
daughter) with breast cancer, women with unknown family history
were excluded.
dOR adjusted for study center, race (non-Hispanic white versus other), age at
mammogram, menopausal status at mammogram, estimated body mass index
at mammogram, age at first diagnosis, age at menarche, number of full-term
pregnancies, histologic type, stage, and estrogen receptor status of first
diagnosis, chemotherapy, radiation, and tamoxifen use after first diagnosis
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MD of 3%), and both remained highly statistically signifi-
cant (p = 0.006 and p = 0.008, respectively). Examination
of chemotherapy categorized by common regimens did
not yield insights into the relevance of specific types of
chemotherapy (Additional file 1: Table S3). Change in
%MD was not associated with radiation therapy catego-
rized as any versus none (Table 6) or by dose categories
(Additional file 1: Table S3). There was no statistical evi-
dence of interaction between radiation and either chemo-
therapy or tamoxifen.
Discussion
In women younger than 55 years at first breast cancer
diagnosis the risk of CBC increased linearly with in-
creasing %MD. The linear association was statistically
significant only for %MD in the post-diagnosis period,
although the magnitudes of the risk estimates were
similar for both time periods. The association with post-
diagnosis %MD may be age-dependent, with stronger
associations for women < 45 years of age and no evi-
dence of association for women aged 50 to 54 years at
first diagnosis; the resulting interaction was marginally
significant (p = 0.06). There was also evidence of re-
duced CBC risk in women with a decrease in %MD of
10% or more between the prior to/at diagnosis and the
post-diagnosis mammogram compared to those with a
change of less than 10%. Chemotherapy was associated
with a decrease in %MD similar to the expected decrease
associated with tamoxifen. Radiation was not associated
with change in %MD. Treatment and other factors such
as ER status are known to be associated with the risk of
CBC [17, 18]. Our results suggest that the addition of
%MD, which is associated with CBC risk independently of
treatment, could improve the prediction of CBC risk, but
factors such as the timing of the mammogram (pre-treat-
ment versus post-treatment) and the age of the woman
should be considered in future studies and CBC risk-
prediction models. Prediction models can help in making
decisions about prophylactic surgery of the contralateral
breast after a first breast cancer diagnosis.
The %MD is well-established as a risk factor for a first
primary breast cancer diagnosis [1]. Adding %MD to
first primary breast cancer risk prediction models has
been shown to improve risk prediction, but only slightly,
with increases in C-statistics of 0.01 to 0.06, reviewed in
[19] and consistent with a mammographic density-based
model compared to the Gail model [20]. Fewer studies
have examined the relationship between %MD and CBC
risk, and they have generally focused on the relationship
between %MD at or prior to diagnosis with CBC risk.
There is some evidence that higher MD at the time of a
DCIS diagnosis is associated with increased risk of DCIS
or invasive cancer in the contralateral breast [6–8]. Simi-
larly, increased risks of any second breast primary or
CBC associated with %MD have been observed among
Table 5 Association of changea in %MD between prior to/at
first diagnosisb and post diagnosisc with CBC risk
Difference in %MD CBCd
Number (%)
UBCd
Number (%)
ORe (95% CI)
Difference <10% 150 (71) 144 (64) 1.00
Decrease ≥10% 60 (29) 81 (36) 0.63 (0.40, 1.01)
Abbreviations: %MD percent mammographic density, CBC contralateral breast
cancer, UBC unilateral breast cancer, OR odds ratio, CI confidence interval
aDefined as the difference between the two time points
bPrior to/at 1st diagnosis was 36 months prior up to 1 month post diagnosis
cPost diagnosis was > 6 months up to 48 months post diagnosis
dExcluding those with missing menopausal status information and those with
an increase ≥10%
eOR adjusted for change in age, estimated body mass index, and menopausal
status between prior to/at first diagnosis and post-diagnosis mammograms
and for initial %MD, study center, race (non-Hispanic white versus other), age
at first diagnosis, age at menarche, number of full-term pregnancies, histologic
type, stage, and estrogen receptor status of first diagnosis, chemotherapy,
radiation, and tamoxifen use after first diagnosis
Table 6 Association between treatment and changea in %MD
Adjusted for age and BMIb Adjusted for age, BMIb, and other treatments
Number Estimated %MD changec 95% CI p Estimated %MD changec 95% CI p
Radiation
No 142 Reference Reference
Yes 325 0.2 −2.1, 2.5 0.89 0.7 −1.6, 3.0 0.57
Chemotherapy
No 161 Reference Reference
Yes 306 −2.9 −5.1, −0.7 0.01 −3.0 −5.2, −0.8 0.008
Tamoxifen
No 238 Reference Reference
Yes 229 −2.8 −4.9, −0.7 0.009 −3.0 −5.1, −0.9 0.006
Abbreviations: %MD percent mammographic density, BMI body mass index, CI confidence interval
aBetween prior to/at first diagnosis (36 months prior up to 1 month post diagnosis) and post diagnosis (more than 6 and up to 48 months post diagnosis)
bEstimated BMI at time of mammogram
cEstimated change in %MD (post diagnosis minus prior to/at diagnosis) associated with each treatment modality
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women with one DCIS or invasive breast cancer diagno-
sis [9–11]. In a study similar to ours, but comparing MD
only at first diagnosis in CBC cases versus UBC controls,
MD was unrelated to CBC risk, although the women in-
cluded in that study were older than the women in our
study [12]. Thus, overall there is some, but not entirely
consistent evidence of an association between %MD at
or prior to diagnosis and CBC risk.
Few studies have considered the relationship between
MD following a first breast cancer diagnosis and CBC
risk. Only one previous study has examined change in
breast density following breast cancer diagnosis and risk
of CBC. This study, which matched on treatment
modalities, observed that a decrease of 10% or more in
MD (%MD or dense area) between first breast cancer
diagnosis and a follow-up mammogram (mostly within 2
years) was associated with a statistically significant re-
duced risk of CBC [12]. Similar to this study, we ob-
served that women with a decrease of 10% or more
following breast cancer diagnosis had a reduced risk of
CBC after adjustment for multiple variables including
treatment, although the relationship was of borderline
statistical significance. The consistency of the two simi-
lar studies suggests that change in %MD could be a use-
ful metric in prediction models of CBC and/or that MD
measured after treatment may be a better predictor of
CBC risk than MD prior to/at diagnosis, or at least a
useful addition to models. Larger studies comparing all
three metrics would be useful.
We found a stronger association of %MD with CBC
risk in younger women, particularly in those < 45 years
of age at first breast cancer diagnosis. There is no evi-
dence that the relationship between MD and the risk of
a first breast cancer varies by age when younger women
are defined as premenopausal, age <50 years, or age <55
years [1, 21], but it is not clear whether there are differ-
ences at younger ages. The %MD generally decreases
with increasing age and during the transition to postmen-
opausal status. As there were relatively few women in the
higher %MD categories at older ages and also following
breast cancer treatment in our study, we likely lacked stat-
istical power to detect significant association between
%MD and CBC risk in women aged 45 –54 years. The
%MD may be a stronger predictor of CBC risk in younger
women, but this finding needs confirmation.
Tamoxifen has been associated with a decrease in MD
in a number of studies [13, 14] and it has been suggested
that the extent of decrease in MD after tamoxifen initi-
ation may be an indicator of response to treatment and
may be related to risk of breast-cancer-related endpoints
[22]. Most of the change in MD that occurs with tam-
oxifen use happens within the first year of use [23].
To our knowledge only two prior studies have assessed
changes in breast density following chemotherapy [12, 15].
In the study of Chen et al., where this was a focus, breast
density was assessed using magnetic resonance imaging in
women receiving neoadjuvant chemotherapy with doxo-
rubicin and cyclophosphamide with or without taxane.
The decrease in density was statistically significant fol-
lowing either chemotherapy regimen [15]. More re-
cently, Sandberg et al. have also shown a significant
decrease in %MD following any chemotherapy with or
without other therapies [12]. These results are consist-
ent with our observed statistically significant reduction
in %MD with any chemotherapy. The decreased density
with chemotherapy may occur as a result of suppres-
sion of the ovary by chemotherapy. No previous studies
have assessed whether radiation exposure has any
direct effect on MD or any moderating influence on the
effect of other treatment modalities.
The strength of our study is that we have detailed
medical record information for our cases and controls,
including tumour characteristics and treatment informa-
tion, as well as other self-reported information relevant
to CBC risk such as family history of breast cancer. To
our knowledge, our study is the first to examine differ-
ences in associations with MD both prior to/at diagnosis
and post diagnosis. Only one prior study evaluated MD
both before and after treatment for a first breast primary
breast cancer, but did not assess the relationship be-
tween post-diagnosis MD and CBC. Our main limitation
is sample size, as we had to retrieve mammograms from
some time in the past and they were frequently unavail-
able, particularly the earlier mammograms. Therefore,
we cannot assess whether %MD from post-diagnostic
mammograms was more strongly associated with risk
than %MD from mammograms prior to/at diagnosis.
Mammogram quality was variable and this likely attenu-
ated our results, although the use of %MD categories
should reduce the misclassification. We also could not
adjust for BMI assessed at the time of the mammogram,
although we were able to estimate this from BMI at two
other time points. Most women in this study had their
initial breast cancer diagnosis during the film mammo-
gram era; however, several studies have demonstrated
that various measures of MD from digital mammograms
are also strongly predictive of breast cancer risk [24–26].
Thus, our results should still be relevant. Also, our
study time period and age distribution means that few
women received aromatase inhibitors. Currently there
is no consistent evidence showing that aromatase inhib-
itors reduce MD [13, 14], although they likely reduce
the risk of CBC [27, 28].
Conclusions
CBC remains a major concern for women diagnosed with
a first breast cancer, but risk is variable and effective risk
prediction models are needed. Such models would be
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essential in making decisions about prophylactic contralat-
eral mastectomy [10]. Given that annual mammography to
screen for new breast primaries in the contralateral breast
is recommended for women with a first breast cancer diag-
nosis [5], it is reasonable to consider MD for inclusion in
CBC prediction models. Our results suggest that post-
diagnosis measures of %MD may be useful to consider in
CBC risk prediction models. Also, %MD may be more pre-
dictive in women aged less than 50 years, although further
research is needed to confirm differences by age. Change
in %MD between before and after treatment should also be
considered, given the potential treatment effects on MD.
Further work is needed to develop and validate clinic-
ally useful CBC risk prediction models considering
comprehensive information (%MD at different time
points, tumour characteristics, treatment, self-reported
risk factors, genetics, etc.) for inclusion and possible
variation by menopausal status or age.
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